Device Trial Radar · NCT01850537
Prospective Study To Assess The Safety and Efficacy of the PROW LIF Procedure
Last checked: Nov 19, 2026Latest source record: May 9, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
15
Planned (sponsor's estimate)
Start
May 2013
Primary completion
Dec 2016
Study completion Dec 2016
Sponsor
- Lead sponsor
- NLT SpineNot on our public-company list
- Sponsor type
- Industry
- First posted
- May 9, 2013
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, single-arm, open-label, non-randomized study. The aim of the study is to assess the safety and efficacy of the Prow LIF procedure in Transforaminal Lumbar Interbody Fusion (TLIF) procedures for the treatment of subjects with symptomatic degenerative disc disease (DDD).
Conditions
- Degenerative Disc Disease
Interventions
treatment of degenerative disc disease using the PROW LIFDevice
TLIF procedure for the treatment of degenerative disc disease using the PROW LIF procedure (system)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Fusion rateTime frame: 24 months follow up
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Spine Surgery Department, Meir Hospital, Israel
Kfar Saba, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.